Blood Work for Peptides: The Complete Monitoring Guide by Protocol (2026)

I run PepPal, maintain a calculator people use to reconstitute every peptide they run, and review every Finnrick test report and COA that lands in the supplier directory. While I was building out the 22 protocol pages on Peptide Dosing Protocols this quarter, one question kept showing up in supplier support threads and Reddit DMs: "Which labs do I actually need for this compound, and when?"

Most existing bloodwork guides are written for clinic patients who have a prescribing physician ordering the panel. That's not the PepPal audience. If you're running a research-use protocol on semaglutide, tirzepatide, CJC-1295/Ipamorelin, BPC-157, or any of the other compounds in the PDP library, you're ordering your own labs - usually through a direct-to-consumer service like Private MD Labs, Request A Test, Grassroots Labs, or Labcorp OnDemand.

This guide is organized by compound, not by peptide category. Pick what you're running, get the panel. That's it.

Research-use disclosure. This is educational content, not medical advice. I'm not a doctor (B.S. Civil Engineering, UCLA). Any listed peptide is either investigational, off-label, or research-use-only depending on jurisdiction. Work with a licensed provider when you can. See my methodology and source tiers.

Lab testing does four specific jobs on a peptide protocol [1]:

1. Efficacy. Did the compound produce its expected biological signal? IGF-1 rising on CJC/Ipamorelin. HbA1c dropping on semaglutide. hs-CRP falling on a Wolverine stack.
2. Safety. Is something silently drifting? Fasting glucose climbing on MK-677 without symptoms. ALT rising from 28 to 62 on a stack without you noticing.
3. Dose calibration. Is the dose too low, right, or too high? IGF-1 at 145 ng/mL is under-dosed. At 385 ng/mL you're overshooting and should cut back.
4. Baseline comparison. If your ALT reads 45 U/L at week 8, is that a problem? Only if you know it was 22 before you started. Without a baseline, every follow-up lab is ambiguous.

Subjective feedback is not a substitute. A patient on MK-677 who "feels great" can have fasting glucose climbing from 92 to 118 over three months - trending toward insulin resistance with zero warning symptoms [1]. Someone four weeks into CJC/Ipamorelin who "feels nothing" may have IGF-1 already moving from 145 to 235 ng/mL - the peptide is working, they just quit too early.

Pick your compound. The table gives you the baseline panel, compound-specific add-ons, and retest cadence. Every compound links to the full PDP protocol page for reconstitution math and titration schedule.

Reading this table. The baseline panel is the minimum draw before your first dose. The compound-specific adds stack on top of the baseline. Retest cadence assumes an 8-week-plus cycle; shorter cycles can compress to baseline + end-of-cycle. For stacked protocols (Wolverine, GLOW, KLOW, CJC/Ipamorelin GH Pulse), run the union of the component panels - I reviewed every stack page on PDP while building this guide, and the union approach is always cleaner than trying to merge sub-panels.

Regardless of which compound you run, five tests form the universal floor. This is true whether you're on a 4-week BPC-157 healing cycle or a 12-month GLP-1 maintenance protocol.

All prices are real vendor quotes I collected while writing this guide in April 2026. Expect 3-8% variance by quarter. Everything routes through Quest Diagnostics or Labcorp patient service centers - the DTC vendor is really just a lab-order writer plus a middle tier.

Tip for cycling users. Most DTC vendors sell "wellness panels" that bundle CMP + CBC + lipid + HbA1c for $35-65. That's your baseline floor regardless of the compound. Buy the bundle; add the compound-specific markers individually.

The standard cycle:

1. Baseline. Within 30 days of your first injection. Closer to the dose is better.
2. First follow-up. 6-8 weeks in. This catches early safety drift (liver enzymes, fasting glucose) and the first meaningful IGF-1 move if you're on a GH peptide.
3. Second check. 3 months in. HbA1c becomes interpretable. Compound-specific efficacy markers settle.
4. Ongoing. Every 3 months during active cycling. Every 6 months in maintenance.
5. Post-cycle. 4-6 weeks after last dose. Confirms reversibility and establishes your next pre-cycle baseline.

Short cycles. For a 4-6 week healing protocol (BPC-157 alone, TB-500 alone, short KPV gut reset), compress to baseline + end-of-cycle. That's two draws covering $60-95 total.

Stacks. For stacked protocols like the Wolverine Stack, GLOW, KLOW, or CJC-1295/Ipamorelin GH Pulse Stack - run the union of the component panels. The CJC/Ipamorelin stack needs the full GH panel. The Wolverine and GLOW need the healing panel plus hs-CRP. KLOW adds copper markers because of the GHK-Cu component.

Any of these means pause the cycle and see a provider:

• ALT or AST above 2x upper limit of normal. Liver stress.
• eGFR below 60 with no other explanation. Kidney function decline.
• Fasting glucose above 126, or HbA1c >= 6.5% on a GH peptide. Diabetic range - the compound may be unmasking insulin resistance.
• IGF-1 above 400 ng/mL. Dose is too high.
• Hematocrit above 54%. Polycythemia - blood clot risk.
• Lipase or amylase above 3x upper limit on a GLP-1. Pancreatitis screen positive.
• Severe abdominal pain radiating to the back on a GLP-1, even with normal labs. Clinical pancreatitis can precede enzyme elevation.
• Any new persistent symptom - breathing changes, calf swelling, sudden vision changes, severe headache - that didn't exist pre-cycle.

1. Skipping baseline because "I've had labs recently." "Recent" on a DTC CMP means within 30 days. A six-month-old CMP is not your baseline for a cycle you're starting this week.
2. Drawing IGF-1 at week 2. Too early. Wait until week 6-8. The lab draw is worthless before then.
3. Taking biotin the morning of an IGF-1 draw. Biotin wrecks the immunoassay. Stop 72 hours before [4].
4. Retesting HbA1c at 4 weeks. HbA1c is a 3-month rolling average. The 4-week number is noise.
5. Not documenting baseline hematocrit. Then a 3-month follow-up shows hematocrit at 51% and nobody knows whether that's a change or just your normal.
6. Running stacked protocols with only a component panel. If you're on BPC-157 plus CJC/Ipamorelin, you need both panels - the healing panel alone misses the IGF-1 monitoring.
7. Measuring creatinine-based eGFR in obese GLP-1 users post-weight-loss. Muscle mass shifts throw creatinine off. Cystatin C gives a truer picture once you're 15%+ into weight loss [2].

1. Pick your compound in the lookup table. Open the linked protocol page for full reconstitution math and titration schedule.
2. Use the PepPal reconstitution calculator to lock in your dose volume before your first injection - matching your planned dose to what's actually in the syringe is part of the pre-cycle workflow.
3. Order your baseline panel through the DTC vendor that's closest to your nearest Quest or Labcorp patient service center. Draw before your first dose.
4. Check current discount codes if you're sourcing compounds - Peptide Partners and Orbitrex both offer PEPPAL codes.
5. Book the week-8 follow-up when you schedule the baseline. You will forget otherwise.

• How to Reconstitute Peptides - the other pre-cycle prep task
• How to Read a Peptide COA - source quality is the other safety variable
• Complete Peptide List - every compound PepPal covers, organized by goal
• Peptide Stacking 101 - stacking implications for labs
• Best Grey Market Peptide Supplier - where to buy if you're building your protocol
• PDP Protocol Library - every protocol with recon math
• PepPal Reconstitution Calculator - free, no-signup math for any vial size

Every number on this page is anchored to one of the sources below. Source tiers follow the hierarchy I use across PepPal and PeptideDosingProtocols.com - see my full methodology for how I grade evidence.

Because this is a monitoring guide rather than a pure efficacy comparison, it leans more heavily on Tier 3 sources than some of the other PepPal blogs. That is intentional. Assay specs, boxed warnings, clinical guidance, and direct-to-consumer lab pricing do not all come from the same source class as Phase 3 obesity trials.